IMDX Short Volume
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, with a market capitalization near $144.9M, listed on NASDAQ, employing roughly 46 people, carrying a beta of 1.77 to the broader market. OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Led by Joshua Riggs, public since 2015-12-30.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-30
- Short Volume
- 29.6K
- Total Volume
- 46.2K
- Short %
- 64.03%
- 30-Day Avg Short %
- 35.84%
Showing 30 days of FINRA short volume data for Insight Molecular Diagnostics Inc..
Learn how short volume is reported and how to read the data →
Frequently asked IMDX short volume questions
- What is the daily IMDX short volume?
- As of Jun 30, 2026, Insight Molecular Diagnostics Inc. (IMDX) short volume is 29.6K shares against 46.2K total reported volume, or 64.03% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is IMDX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does IMDX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.